A Silent Crisis: COPD's Rising Threat in Australia
In a concerning development, Australians battling Chronic Obstructive Pulmonary Disease (COPD) are facing a double-edged challenge. As the disease's prevalence soars, a critical diagnostic tool, spirometry, is being underutilized, especially in Western NSW, where COPD treatment rates are the highest in the country.
COPD, an incurable lung disease, causes breathlessness, coughing, and potentially life-threatening flare-ups. It damages lung tissue, making breathing increasingly difficult. A recent Evohealth report reveals a shocking statistic: COPD claims more Australian lives annually than breast and prostate cancers combined, costing the health system a staggering $1.67 billion.
But here's where it gets controversial...
While COPD rates are projected to rise, with an expected increase from 526,000 to over 843,000 cases by 2050, spirometry testing has seen a 31% decline between 2015-16 and 2022-23. This simple breathing test is crucial for an accurate diagnosis, yet half of those with COPD remain undiagnosed.
Without spirometry, patients risk misdiagnosis and inappropriate medication, which can be harmful. Dr. Lee Fong, the Commission's Medical Advisor, emphasizes the importance of this test for those with recurrent breathing issues and risk factors like smoking.
And this is the part most people miss...
As spirometry rates drop, the use of complex COPD medications, particularly triple therapy, is surging. The Western NSW Primary Health Network has the highest rate of triple-therapy prescriptions in Australia. These medications are typically reserved for severe cases, indicating a rising number of patients with advanced, difficult-to-manage COPD.
Professor Christine Jenkins, a respiratory specialist, highlights the challenges faced by rural and remote communities, where delayed diagnosis and inconsistent access to care lead to reliance on long-term medication or emergency hospital visits.
A Disease of Inequality
COPD rates are three times higher in disadvantaged areas compared to affluent ones, with significant disparities in regional and remote regions. Dust exposure, smoking, air pollution, and agricultural work contribute to this rural burden. First Nations people are disproportionately affected, especially in regional and remote communities, where structural and socioeconomic disadvantages persist.
Evohealth's Managing Director, Renae Beardmore, emphasizes that the combination of these factors means people in rural areas are more likely to develop COPD and face earlier deaths from the disease.
Experts stress the urgency of refocusing on early, evidence-based diagnosis and appropriate prescribing. COPD is a leading cause of preventable hospitalizations in Australia, and the data shows a dramatic rise in triple therapy while spirometry use has plummeted.
The Commission's new COPD Clinical Care Standard aims to improve access to diagnosis, specialist care, and treatment consistency nationwide. For regional Australians, the challenge is ensuring these standards reach those most in need, preventing a simple cough from becoming a critical health crisis.
